Clinical Trial Detail

NCT ID NCT03592264
Title This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OBI Pharma, Inc
Indications

prostate cancer

Advanced Solid Tumor

Therapies

OBI-3424

Age Groups: adult senior

No variant requirements are available.